Literature DB >> 19276015

Patients' perceptions of generic medications.

William H Shrank1, Emily R Cox, Michael A Fischer, Jyotsna Mehta, Niteesh K Choudhry.   

Abstract

Insurers and policymakers encourage the use of generic drugs to reduce costs, but generics remain underused. We conducted a national survey of commercially insured adults to evaluate their perceptions about generic drugs. Patients agreed that generics are less expensive and a better value than brand-name drugs, and are just as safe. However, although 56 percent reported that Americans should use more generics, only 37.6 percent prefer to take generics. We discuss perceptions about communicating with practitioners about generics, generic substitution, and policymakers' role in influencing generic use. These findings underscore the challenge that providers, insurers, and policymakers face in stimulating the cost-effective use of medications.

Entities:  

Mesh:

Year:  2009        PMID: 19276015      PMCID: PMC2748784          DOI: 10.1377/hlthaff.28.2.546

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  10 in total

1.  Consumer perceptions of risk and required cost savings for generic prescription drugs.

Authors:  J M Ganther; D H Kreling
Journal:  J Am Pharm Assoc (Wash)       Date:  2000 May-Jun

2.  Brand substitution the consumer's viewpoint.

Authors:  A A Nelson; J P Gagnon
Journal:  J Am Pharm Assoc       Date:  1975-07       Impact factor: 2.217

Review 3.  Multiple imputation in health-care databases: an overview and some applications.

Authors:  D B Rubin; N Schenker
Journal:  Stat Med       Date:  1991-04       Impact factor: 2.373

4.  Impact of alternative interventions on changes in generic dispensing rates.

Authors:  A James O'Malley; Richard G Frank; Atheer Kaddis; Barbara M Rothenberg; Barbara J McNeil
Journal:  Health Serv Res       Date:  2006-10       Impact factor: 3.402

5.  Commercial features of placebo and therapeutic efficacy.

Authors:  Rebecca L Waber; Baba Shiv; Ziv Carmon; Dan Ariely
Journal:  JAMA       Date:  2008-03-05       Impact factor: 56.272

6.  The effect of pharmacy benefit design on patient-physician communication about costs.

Authors:  William H Shrank; Sarah A Fox; Adele Kirk; Susan L Ettner; Clairessa H Cantrell; Peter Glassman; Steven M Asch
Journal:  J Gen Intern Med       Date:  2006-04       Impact factor: 5.128

7.  Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000.

Authors:  Jennifer S Haas; Kathryn A Phillips; Eric P Gerstenberger; Andrew C Seger
Journal:  Ann Intern Med       Date:  2005-06-07       Impact factor: 25.391

8.  Economic implications of evidence-based prescribing for hypertension: can better care cost less?

Authors:  Michael A Fischer; Jerry Avorn
Journal:  JAMA       Date:  2004-04-21       Impact factor: 56.272

9.  Allergic to generics.

Authors:  Troyen A Brennan; Thomas H Lee
Journal:  Ann Intern Med       Date:  2004-07-20       Impact factor: 25.391

10.  The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions.

Authors:  William H Shrank; Tuyen Hoang; Susan L Ettner; Peter A Glassman; Kavita Nair; Dee DeLapp; June Dirstine; Jerry Avorn; Steven M Asch
Journal:  Arch Intern Med       Date:  2006-02-13
  10 in total
  78 in total

1.  Comparison of Generic-to-Brand Switchback Rates Between Generic and Authorized Generic Drugs.

Authors:  Richard A Hansen; Jingjing Qian; Richard Berg; James Linneman; Enrique Seoane-Vazquez; Sarah K Dutcher; Saeid Raofi; C David Page; Peggy Peissig
Journal:  Pharmacotherapy       Date:  2017-03-20       Impact factor: 4.705

Review 2.  Bioequivalence; its history, practice, and future.

Authors:  Kamal K Midha; Gordon McKay
Journal:  AAPS J       Date:  2009-10-06       Impact factor: 4.009

3.  Predictors of statin compliance after switching from branded to generic agents among managed-care beneficiaries.

Authors:  Robert J Romanelli; Jodi B Segal
Journal:  J Gen Intern Med       Date:  2014-06-24       Impact factor: 5.128

4.  Product-Specific Regulatory Pathways to Approve Generic Drugs: The Need for Follow-up Studies to Ensure Safety and Effectiveness.

Authors:  Aaron S Kesselheim; Joshua J Gagne
Journal:  Drug Saf       Date:  2015-10       Impact factor: 5.606

5.  The economic impact of the transition from branded to generic oncology drugs.

Authors:  W Y Cheung; E A Kornelsen; N Mittmann; N B Leighl; M Cheung; K K Chan; P A Bradbury; R C H Ng; B E Chen; K Ding; J L Pater; D Tu; A E Hay
Journal:  Curr Oncol       Date:  2019-04-01       Impact factor: 3.677

Review 6.  The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?

Authors:  Gianluca Trifirò; Rosa Gini; Francesco Barone-Adesi; Ettore Beghi; Anna Cantarutti; Annalisa Capuano; Carla Carnovale; Antonio Clavenna; Mirosa Dellagiovanna; Carmen Ferrajolo; Matteo Franchi; Ylenia Ingrasciotta; Ursula Kirchmayer; Francesco Lapi; Roberto Leone; Olivia Leoni; Ersilia Lucenteforte; Ugo Moretti; Alessandro Mugelli; Luigi Naldi; Elisabetta Poluzzi; Concita Rafaniello; Federico Rea; Janet Sultana; Mauro Tettamanti; Giuseppe Traversa; Alfredo Vannacci; Lorenzo Mantovani; Giovanni Corrao
Journal:  Drug Saf       Date:  2019-03       Impact factor: 5.606

7.  Determinants of Generic Drug Substitution in the United States.

Authors:  Jodi B Segal; Oluwadamilola Onasanya; Matthew Daubresse; Chia-Ying Lee; Mischka Moechtar; Xia Pu; Sarah K Dutcher; Robert J Romanelli
Journal:  Ther Innov Regul Sci       Date:  2020-01-06       Impact factor: 1.778

8.  A comparative evaluation of price and quality of some branded versus branded-generic medicines of the same manufacturer in India.

Authors:  G L Singal; Arun Nanda; Anita Kotwani
Journal:  Indian J Pharmacol       Date:  2011-04       Impact factor: 1.200

Review 9.  Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.

Authors:  Aaron S Kesselheim; Alexander S Misono; Joy L Lee; Margaret R Stedman; M Alan Brookhart; Niteesh K Choudhry; William H Shrank
Journal:  JAMA       Date:  2008-12-03       Impact factor: 56.272

10.  Regional Variation in Physician Adoption of Antipsychotics: Impact on US Medicare Expenditures.

Authors:  Julie M Donohue; Sharon-Lise T Normand; Marcela Horvitz-Lennon; Aiju Men; Ernst R Berndt; Haiden A Huskamp
Journal:  J Ment Health Policy Econ       Date:  2016-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.